Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

Updated data on IBI363 monotherapy in patients with advanced NSCLC were reported (ClinicalTrials.gov, NCT05460767). As of the ...

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic ...

In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic ...

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO: San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc ...

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.